The PfATP4 (PF3D7 1211900) multi-drug resistance mutation G223R is found in Africa by genetically analyzing 2640 worldwide Plasmodium falciparum blood stage isolates (the MalariaGen Pf3k resource). This mutation confers an approximate 8 fold [4] [4] . It is postulated that the G223R mutation may be a consequence of the drug resistant Southeast Asian Dd2 genotype becoming more dominant in Africa [3] . The presence of this mutation has important policy implications for the eventual general deployment of the Spiroindolone KAE609 (Cipargamin) which is currently undergoing stage 2 clinical trials.
Introduction
Advances in laboratory automation, process control software and automated biological detectors have allowed malaria researchers to perform high-throughput screening (HTS) of very large chemical libraries [6] [4] to find candidate antimalarial drugs. This HTS screening has been successful in identifying novel anti-malarial drugs including KAE609 [6] . Screens often use whole-cell assays to determine likely candidates. A straightforward method of determining the location and action of the HTS drug candidates is to pressure Plasmodium falciparum (Pf) laboratory strains and map the resultant genetic mutations that confer resistance.
Many resistance conferring mutations of novel HTS candidates have mapped to the transmembrane ATPase sodium pump [15] [16] PfATP4 (PF3D7 1211900) indicating that the likely HTS candidate action is the inhibition of this protein. A literature search reveals 54 mutations in PfATP4 conferring 1 resistance. These are tabulated in table 4 for the convenience of the reader. Many of the mutations confer resistance to multiple HTS candidates from different compound classes [16] .
The MalariaGen consortium Malaria 3000 (Pf3k) project has processed 2640 genetically sequenced blood stage Pf isolates (128 laboratory, 2512 field) using GATK 1 best practices into Variant Calling File (VCF) format. This wonderful genetic resource removes the need for the considerable technical and computing infrastructure needed to go from raw short read FASTQ sequence files, via sorted BAM files, to properly generated VCF files 2 . An immediate use of the Pf3k resource is to check for the existence of drug resistance conferring mutations in geographically distinct Pf populations.
This was done by Gomes et al [5] for a number of drug target proteins including PfATP4 using Delly software (Rausch et al [13] ) to analyze Pf3k BAM files and generate variants 3 .
The results tabulated by Gomes et al [5] are different to the results of this research. In particular, Gomes et al [5] do not report the PfATP4 synonymous SNP G223G (C669A, 35% of all isolates) characteristic of the Pf strain Dd2 [14] or G223S (G667A, 8.9% of all isolates) present in African populations. It should be noted that the G667A and C669A SNPs (GGC→AGA) occuring together produce the G223R resistance mutation. The probable reason for the difference between Gomes et al [5] and this research appears to be different variant calling methodology. Whereas Gomes et al [5] use Delly (Rausch et al [13] ) to call variants, this research does not attempt to independently discover variants, but uses the Pf3k VCF files generated by MalariaGen using GATK. The VCF files are then post-processed by kgl genome software developed for this and subsequent Pf genetic research by the author (details in the Methods and Data appendix).
PfATP4 Mutations in Model Pf Organisms
The MalariaGen Pf3k whole genome sequence (WGS) dataset includes 5 laboratory model Pf 
The Geographic Distribution of G223R
The geography of the G223R mutation is tabulated below in table 2. The table gives the proportion of the three mutually exclusive mutations of codon 223 in PfATP4 and the synonymous mutation A229A (T687A). The Southeast Asian locations that do not have G223S or G223R (G667A) mutations are not tabulated. The synonymous mutation G223G (C669A) is characteristic of the Dd2 model organism [14] and is, as expected, prevalent in Southeast Asia. In particular it is present in 72% of the Ramu, Bangladesh isolates tabulated below. The presence of C669A brings the Pf organism to within 1 SNP of G223R with the subsequent addition of G667A. However, only populations with the G223S (G667A) mutation have also acquired the G223R mutation, strongly suggesting that this mutation is acquired by the subsequent addition of C669A to an existing G667A genotype.
The G223R mutation may be a consequence of the drug resistant Southeast Asian Dd2 genotype becoming more dominant in Africa [3] with this gene flow adding the Dd2 characteristic mutation G223G (C669A) to existing G223S (G667A) African sub-populations.
We also find very high linkage dis-equilibrium between G667A and T687A (A229A). This disequilibrium is tabulated as a Pearson correlation (correlations with p > 0.01 are not shown). This may be an artifact of an ancestor genotype that has not decayed to linkage equilibrium through recombination because of the proximity of the SNPs. However, there is no similar magnitude of linkage dis-equilibrium with other nearby SNPs such as C669A. 6 See the relevant Pf3K documentation at MalariaGen at https://www.malariagen.net/.
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G223R and Multi-Drug Resistance
Rottmann et al [14] find the G223R mutation in one of the Dd2 strains (NITD678-RDd2 clone#1)
they pressured with Spiroindolone KAE678 and speculate that the G223R mutation may not be a result of evolved resistance to KAE678. Manary et al [10] pressured Dd2 strains with KAE678 for 2-4 months and found the G223R mutation in the resultant drug resistant strain. Flannery et al [4] show an approximate 8 fold increase in the IC 50 of GNF-Pf4492, KAE609 and KAE678
for G223R mutated Dd2. Spillman and Kirk [16] show that the NITD678-RDd2 clone#1 strain developed by Rottmann et al [14] has an KAE678 EC 50 of 193 ± 39 nM compared to 21.9 ± 1.2 nM for the Dd2 wildtype. This is an approximate 9 fold increase and is consistent with results found by Flannery et al [4] . Finally, Jiménez-Díaz et al [7] mention G223R as a drug resistant mutation for the Dihydroisoquinolone SJ733 but provide no further detail.
The presence of the G223R mutation at moderate but significant levels in Africa has important policy implications for the development and deployment of the new generation of anti-malarial drugs which are active against the ATPase sodium pump PfATP4. One of the most promising of these anti-malarials, KAE609 (Cipargamin) is currently (March 2018) undergoing stage 2 clinical trials. The possibility that the G223R mutation may be a result of the drug resistant Southeast Asian Dd2 genotype becoming more dominant in Africa [3] and the very high linkage dis-equilibrium between the SNPs G667A and T687A are interesting topics that merit further research. The kgl genome library uses third party libraries (documented on GitHub) notably the Seqan [2] genome sequence library for advanced sequence comparison and manipulation. Finally, output from kgl genome is examined using tools that will be familar to readers such as Excel and R to produce the final SNP list (no indels were detected in PfATP4). The FASTA and GFF files used by kgl genome were obtained from Plasmodb (http://plasmodb.org) release 35 (1 December 2017).
Methods and Data Appendix
The identification of SNPs and other variants is a trade-off between sensitivity and specificity; the kgl genome software parses the MalariaGen VCF files and filters variants using the following quality metrics: (1) the Phred-scaled probability that a REF/ALT polymorphism exists, QUAL ≥ 100;
(2) the log of the ratio of the probability that a called variant is true over the probability that the called variant is false (log
For each filtered variant, each of the 2640 isolates are individually filtered for depth of coverage, DP ≥ 10 and the Phred-scaled confidence that the isolate genotype assignment is correct, GQ ≥ 20.
After parsing and filtering the VCF file the kgl genome software converts the filtered isolate variant information into an internal variant format and, for each isolate, mutates the reference PfATP4
DNA sequence with the filtered variants obtained for each isolate. This reconstructed mutated DNA sequence is then compared to the reference DNA sequence using the Seqan [2] genome sequence library and a list of variants is generated from the results of this comparison. This indirect method of extracting isolate variant information has the advantage of examining reconstructed mutated DNA using the familiar Needleman Wunsch algorithm and does not assume VCF called variants are independent or mutually exclusive.
This process generates 188 distinct SNP variants from the 2640 isolates. The majority of the distinct SNPs, 110, are found in only 1 or 2 isolates. There are 22 SNPs that are found in ≥ 1% of all isolates and these are tabulated below in table 3. 
Other Resistance Mutations
A literature search found 54 PfATP4 drug resistance mutations and these are listed in table 4.
The 188 distinct SNP variants from the 2640 isolates are examined to see if any occur in the same codon as the tabulated resistance mutations. There are 2 synonymous mutations, P990P (A2970T, CCA→CCT, 5 isolates) and Q172Q (A516G, CAA→CAG, 1 isolate) that map to resistance codons.
However, unlike the synonymous G223G (C669A) SNP, these synonymous SNPs do not increase the probability of the corresponding resistance mutations occurring: P990R (CCA→CG*), Q172H
(CAA→CAC,CAT), Q172K (CAA→AAG,AAA).
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